Myeloproliferative Neoplasms MPN

MYELOPROLIFERATIVE NEOPLASMS MPN NEWS TIPS & FEATURES

CTI BioPharma Announces Removal Of Full Clinical Hold On Pacritinib

January 6th, 2017

CTI BioPharma Announces Removal Of Full Clinical Hold On Pacritinib

CTI BioPharma Corp. announced that the full clinical hold (February 2016) implemented by the U.S. Food and Drug Administration (FDA) on all clinical trials conducted […]


5-Year Survival Improved with Early Use of Jakafi® in Myelofibrosis

December 20th, 2016

5-Year Survival Improved with Early Use of Jakafi® in Myelofibrosis

An analysis of 5-year data from two large clinical trials provide conclusive support that treatment with Jakafi® (ruxolitinib) improves long-term survival, compared to other treatment […]


Interferon No Better Than Hydroxyurea and Associated with Worse Side Effects in Polycythemia Vera and Essential Thrombocythemia

December 16th, 2016

Interferon No Better Than Hydroxyurea and Associated with Worse Side Effects in Polycythemia Vera and Essential Thrombocythemia

The use of interferon as initial therapy in MPN is associated with worsening side effects the longer it is used for treatment. These results were […]


Duration of Blood Storage Does Not Affect Outcomes for Patients Requiring Blood Transfusions

December 1st, 2016

Duration of Blood Storage Does Not Affect Outcomes for Patients Requiring Blood Transfusions

The length of time that blood is stored prior to a blood transfusion, within normal ranges, does not appear to affect mortality among patients requiring […]


Myeloproliferative Neoplasms Greatly Affect Patient Quality of Life

October 10th, 2016

Myeloproliferative Neoplasms Greatly Affect Patient Quality of Life

According to results from the myeloproliferative neoplasms (MPN) Landmark survey, MPN’s negatively affect the quality of life and overall health of patients even a year […]


Jakafi Superior to Standard Treatment in Polycythemia Vera

June 21st, 2016

Jakafi Superior to Standard Treatment in Polycythemia Vera

Treatment with Jakafi® (ruxolitinib) was superior to best available treatment among patients with inadequately controlled polycythemia vera (PV). These results were recently presented at the […]


Jakafi Significantly Improves Long-Term Outcomes in Myelofibrosis

June 7th, 2016

Jakafi Significantly Improves Long-Term Outcomes in Myelofibrosis

The agent Jakafi® (ruxolitinib) has demonstrated significant improvements in long-term outcomes for patients diagnosed with myelofibrosis. These results were recently presented at the 2016 annual meeting […]


Polycythemia Vera Today

May 19th, 2016

Polycythemia Vera Today

Polycythemia vera (PV) is a type of blood cancer known as a myeloproliferative neoplasm. It involves the abnormal development and function of bone marrow cells […]


Pacritinib Development in Myelofibrosis Placed on Clinical Hold by the FDA

April 20th, 2016

Pacritinib Development in Myelofibrosis Placed on Clinical Hold by the FDA

The investigative agent, pacritinib, being evaluated for treatment of myelofibrosis has been placed on full clinical hold by the United States Food and Drug Administration […]


MPN Research Foundation Launches CancerConnect Social Media Platform

March 2nd, 2016

MPN Research Foundation Launches CancerConnect Social Media Platform

Austin TX/Sun Valley ID– With the launch of the CancerConnect online community, the MPN Research Foundation (MPNRF) now offers a specialized social network for individuals […]


More News →